<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:media="http://search.yahoo.com/mrss/" xmlns:ynews="http://news.yahoo.com/rss/">
    <channel>
        <title>Nova Reader - Subject</title>
        <link>https://www.novareader.co</link>
        <description>Default RSS Feed</description>
        <language>en-us</language>
        <copyright>Newgen KnowledgeWorks</copyright>
        <item>
            <title><![CDATA[Global patterns of avian influenza A (H7): virus evolution and zoonotic threats]]></title>
            <media:thumbnail url="https://storage.googleapis.com/nova-demo-unsecured-files/unsecured/content-1766024084911-44be8735-cafd-4b18-9424-bfaabc56776e/cover.png"></media:thumbnail>
            <link>https://www.novareader.co/book/isbn/10.1093/femsre/fuz019</link>
            <description><![CDATA[<p class="para" id="N65541">Avian influenza viruses (AIVs) continue to impose a negative impact on animal and human health worldwide. In particular, the emergence of highly pathogenic AIV H5 and, more recently, the emergence of low pathogenic AIV H7N9 have led to enormous socioeconomical losses in the poultry industry and resulted in fatal human infections. While H5N1 remains infamous, the number of zoonotic infections with H7N9 has far surpassed those attributed to H5. Despite the clear public health concerns posed by AIV H7, it is unclear why specifically this virus subtype became endemic in poultry and emerged in humans. In this review, we bring together data on global patterns of H7 circulation, evolution and emergence in humans. Specifically, we discuss data from the wild bird reservoir, expansion and epidemiology in poultry, significant increase in their zoonotic potential since 2013 and genesis of highly pathogenic H7. In addition, we analysed available sequence data from an evolutionary perspective, demonstrating patterns of introductions into distinct geographic regions and reassortment dynamics. The integration of all aspects is crucial in the optimisation of surveillance efforts in wild birds, poultry and humans, and we emphasise the need for a One Health approach in controlling emerging viruses such as AIV H7.</p><p class="para" id="N65540">H7 avian influenza virus causes infections in birds and mammals and is of pandemic concern; our review brings together data from the ecology, veterinary and human health points of view and demonstrates the importance of ‘One Heath’ in the long-term management of this virus.</p>]]></description>
            <pubDate><![CDATA[2019-08-05T00:00]]></pubDate>
        </item><item>
            <title><![CDATA[Recent trends in molecular diagnostics of yeast infections: from PCR to NGS]]></title>
            <media:thumbnail url="https://storage.googleapis.com/nova-demo-unsecured-files/unsecured/content-1766023675906-8a6a3232-0ea5-48b0-8a85-81bfaa9e7347/cover.png"></media:thumbnail>
            <link>https://www.novareader.co/book/isbn/10.1093/femsre/fuz015</link>
            <description><![CDATA[<p class="para" id="N65541">The incidence of opportunistic yeast infections in humans has been increasing over recent years. These infections are difficult to treat and diagnose, in part due to the large number and broad diversity of species that can underlie the infection. In addition, resistance to one or several antifungal drugs in infecting strains is increasingly being reported, severely limiting therapeutic options and showcasing the need for rapid detection of the infecting agent and its drug susceptibility profile. Current methods for species and resistance identification lack satisfactory sensitivity and specificity, and often require prior culturing of the infecting agent, which delays diagnosis. Recently developed high-throughput technologies such as next generation sequencing or proteomics are opening completely new avenues for more sensitive, accurate and fast diagnosis of yeast pathogens. These approaches are the focus of intensive research, but translation into the clinics requires overcoming important challenges. In this review, we provide an overview of existing and recently emerged approaches that can be used in the identification of yeast pathogens and their drug resistance profiles. Throughout the text we highlight the advantages and disadvantages of each methodology and discuss the most promising developments in their path from bench to bedside.</p><p class="para" id="N65540">The authors discuss the current status of the use of high-throughput (-omics) technologies on the diagnostics of yeast infections.</p>]]></description>
            <pubDate><![CDATA[2019-06-03T00:00]]></pubDate>
        </item><item>
            <title><![CDATA[Human influenza A virus causes myocardial and cardiac-specific conduction
system infections associated with early inflammation and premature death]]></title>
            <media:thumbnail url="https://storage.googleapis.com/nova-demo-unsecured-files/unsecured/content-1765905823870-a5355d87-7efc-4fb8-8693-b643ff6c9ae8/cover.png"></media:thumbnail>
            <link>https://www.novareader.co/book/isbn/10.1093/cvr/cvaa117</link>
            <description><![CDATA[<div class="section" id="s1"><h3 class="BHead" id="nov000-1">Aims</h3><p class="para" id="N65545">Human influenza A virus (hIAV) infection is associated with important cardiovascular
complications, although cardiac infection pathophysiology is poorly understood. We aimed
to study the ability of hIAV of different pathogenicity to infect the mouse heart, and
establish the relationship between the infective capacity and the associated <i>in
vivo</i>, cellular and molecular alterations.</p></div><div class="section" id="s2"><h3 class="BHead" id="nov000-2">Methods and results</h3><p class="para" id="N65555">We evaluated lung and heart viral titres in mice infected with either one of several
hIAV strains inoculated intranasally. 3D reconstructions of infected cardiac tissue were
used to identify viral proteins inside mouse cardiomyocytes, Purkinje cells, and cardiac
vessels. Viral replication was measured in mouse cultured cardiomyocytes. Human-induced
pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs) were used to confirm infection
and study underlying molecular alterations associated with the <i>in vivo</i>
electrophysiological phenotype. Pathogenic and attenuated hIAV strains infected and
replicated in cardiomyocytes, Purkinje cells, and hiPSC-CMs. The infection was also
present in cardiac endothelial cells. Remarkably, lung viral titres did not
statistically correlate with viral titres in the mouse heart. The highly pathogenic
human recombinant virus PAmut showed faster replication, higher level of inflammatory
cytokines in cardiac tissue and higher viral titres in cardiac HL-1 mouse cells and
hiPSC-CMs compared with PB2mut-attenuated virus. Correspondingly, cardiac conduction
alterations were especially pronounced in PAmut-infected mice, associated with high
mortality rates, compared with PB2mut-infected animals. Consistently, connexin43 and
Na<sub>V</sub>1.5 expression decreased acutely in hiPSC-CMs infected with PAmut virus.
YEM1L protease also decreased more rapidly and to lower levels in PAmut-infected
hiPSC-CMs compared with PB2mut-infected cells, consistent with mitochondrial
dysfunction. Human IAV infection did not increase myocardial fibrosis at 4-day
post-infection, although PAmut-infected mice showed an early increase in mRNAs
expression of lysyl oxidase.</p></div><div class="section" id="s3"><h3 class="BHead" id="nov000-3">Conclusion</h3><p class="para" id="N65568">Human IAV can infect the heart and cardiac-specific conduction system, which may
contribute to cardiac complications and premature death.</p></div><p class="para" id="N65542">
<div class="section" id="ga1"><div class="img"><div class="imgeVideo"><div class="img-fullscreenIcon" onClick="javascript:showImageContent('ga1');"><img src="/public/images/journalImg/fullscreen.png"/></div><div class="imageVideo"><img src="/dataresources/secured/content-1765905823870-a5355d87-7efc-4fb8-8693-b643ff6c9ae8/assets/cvaa117f8.jpg" alt=""/></div></div></div></div>
</p>]]></description>
            <pubDate><![CDATA[2020-05-20T00:00]]></pubDate>
        </item><item>
            <title><![CDATA[NF1 optic pathway glioma: analyzing risk factors for visual outcome and indications to treat]]></title>
            <media:thumbnail url="https://storage.googleapis.com/nova-demo-unsecured-files/unsecured/content-1765823988985-e1021aa6-4af2-45f0-aacf-59cbbcae71a6/cover.png"></media:thumbnail>
            <link>https://www.novareader.co/book/isbn/10.1093/neuonc/noaa153</link>
            <description><![CDATA[<div class="section" id="s0100"><h3 class="BHead" id="nov000-1">Background</h3><p class="para" id="N65545">The aim of the project was to identify risk factors associated with visual progression and treatment indications in pediatric patients with neurofibromatosis type 1 associated optic pathway glioma (NF1-OPG).</p></div><div class="section" id="s0101"><h3 class="BHead" id="nov000-2">Methods</h3><p class="para" id="N65551">A multidisciplinary expert group consisting of ophthalmologists, pediatric neuro-oncologists, neurofibromatosis specialists, and neuro-radiologists involved in therapy trials assembled a cohort of children with NF1-OPG from 6 European countries with complete clinical, imaging, and visual outcome datasets. Using methods developed during a consensus workshop, visual and imaging data were reviewed by the expert team and analyzed to identify associations between factors at diagnosis with visual and imaging outcomes.</p></div><div class="section" id="s0102"><h3 class="BHead" id="nov000-3">Results</h3><p class="para" id="N65557">Eighty-three patients (37 males, 46 females, mean age 5.1 ± 2.6 y; 1–13.1 y) registered in the European treatment trial SIOP LGG-2004 (recruited 2004–2012) were included. They were either observed or treated (at diagnosis/after follow-up).</p><p class="para" id="N65559">In multivariable analysis, factors present at diagnosis associated with adverse visual outcomes included: multiple visual signs and symptoms (adjusted odds ratio [adjOR]: 8.33; 95% CI: 1.9–36.45), abnormal visual behavior (adjOR: 4.15; 95% CI: 1.20–14.34), new onset of visual symptoms (adjOR: 4.04; 95% CI: 1.26–12.95), and optic atrophy (adjOR: 3.73; 95% CI: 1.13–12.53). Squint, posterior visual pathway tumor involvement, and bilateral pathway tumor involvement showed borderline significance. Treatment appeared to reduce tumor size but improved vision in only 10/45 treated patients. Children with visual deterioration after primary observation are more likely to improve with treatment than children treated at diagnosis.</p></div><div class="section" id="s0103"><h3 class="BHead" id="nov000-4">Conclusions</h3><p class="para" id="N65565">The analysis identified the importance of symptomatology, optic atrophy, and history of vision loss as predictive factors for poor visual outcomes in children with NF1-OPG.</p></div>]]></description>
            <pubDate><![CDATA[2020-07-06T00:00]]></pubDate>
        </item><item>
            <title><![CDATA[Regional and global contributions of air pollution to risk of death from
COVID-19]]></title>
            <media:thumbnail url="https://storage.googleapis.com/nova-demo-unsecured-files/unsecured/content-1765759801089-cfe50676-b8c0-4505-b9e3-0d44d7e32747/cover.png"></media:thumbnail>
            <link>https://www.novareader.co/book/isbn/10.1093/cvr/cvaa288</link>
            <description><![CDATA[<div class="section" id="s1"><h3 class="BHead" id="nov000-1">Aims</h3><p class="para" id="N65545">The risk of mortality from the coronavirus disease that emerged in 2019 (COVID-19) is
increased by comorbidity from cardiovascular and pulmonary diseases. Air pollution also
causes excess mortality from these conditions. Analysis of the first severe acute
respiratory syndrome coronavirus (SARS-CoV-1) outcomes in 2003, and preliminary
investigations of those for SARS-CoV-2 since 2019, provide evidence that the incidence
and severity are related to ambient air pollution. We estimated the fraction of COVID-19
mortality that is attributable to the long-term exposure to ambient fine particulate air
pollution.</p></div><div class="section" id="s2"><h3 class="BHead" id="nov000-2">Methods and results</h3><p class="para" id="N65551">We characterized global exposure to fine particulates based on satellite data, and
calculated the anthropogenic fraction with an atmospheric chemistry model. The degree to
which air pollution influences COVID-19 mortality was derived from epidemiological data
in the USA and China. We estimate that particulate air pollution contributed ∼15% (95%
confidence interval 7–33%) to COVID-19 mortality worldwide, 27% (13 – 46%) in East Asia,
19% (8–41%) in Europe, and 17% (6–39%) in North America. Globally, ∼50–60% of the
attributable, anthropogenic fraction is related to fossil fuel use, up to 70–80% in
Europe, West Asia, and North America.</p></div><div class="section" id="s3"><h3 class="BHead" id="nov000-3">Conclusion</h3><p class="para" id="N65557">Our results suggest that air pollution is an important cofactor increasing the risk of
mortality from COVID-19. This provides extra motivation for combining ambitious policies
to reduce air pollution with measures to control the transmission of COVID-19.</p></div>]]></description>
            <pubDate><![CDATA[2020-10-26T00:00]]></pubDate>
        </item>
    </channel>
</rss>